Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female and between the ages of 20 and 75 years diagnosed with dyslipidemia~Exclusion Criteria:~* Patients has Coronary Heart Disease (CHD) or CHD-equivalent disease (except diabetes)~* Patients has uncontrolled diabetes~* Patient is currently participating or has participated in a study with an investigational compound within the last 3 months

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MK0859 10 mg + placebo
- 2 (Type: EXPERIMENTAL): MK0859 40 mg + placebo
- 3 (Type: EXPERIMENTAL): MK0859 100 mg + placebo
- 4 (Type: EXPERIMENTAL): MK0859 300 mg + placebo
- 5 (Type: EXPERIMENTAL): MK0859 10 mg + atorvastatin 10mg
- 6 (Type: EXPERIMENTAL): MK0859 40 mg + atorvastatin 10mg
- 7 (Type: EXPERIMENTAL): MK0859 100 mg + atorvastatin 10mg
- 8 (Type: EXPERIMENTAL): MK0859 300 mg + atorvastatin 10mg
- 9 (Type: PLACEBO_COMPARATOR): Placebo + atorvastatin 10mg
- 10 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).